Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Regulatory Releases
  • Press Releases
  • All releases
2020
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
December 28, 2020

Oasmia’s partner Elevar Therapeutics signs licensing agreement with Inceptua Group for the commercialization of Apealea® (paclitaxel micellar) in Europe

Regulatory
December 9, 2020

Interim report1 for the period May 1, 2020 – October 31, 2020

Regulatory
December 3, 2020

Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer

Regulatory
November 20, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia

Regulatory
October 14, 2020

The Disciplinary Committee of Nasdaq Stockholm orders Oasmia to pay a fine

Regulatory
October 5, 2020

Oasmia’s partner Elevar Therapeutics signs agreement with Taiba Middle East FZ LLC for commercialization of Apealea® in the Middle East and North Africa Region

Regulatory
September 25, 2020

Oasmia Brings an Action against the Former Board of Directors

Regulatory
September 9, 2020

Report from Annual General Meeting of Oasmia Pharmaceutical AB

Regulatory
September 9, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2020

Regulatory
September 8, 2020

Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer

Regulatory
September 2, 2020

Oasmia’s Nomination Committee revises its proposal for the AGM regarding Board of Directors

Regulatory
August 31, 2020

CFO of Oasmia, Michael af Winklerfelt has resigned

Regulatory
August 19, 2020

Oasmia publishes its annual report

Regulatory
August 10, 2020

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory
July 27, 2020

Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea®

Regulatory
June 18, 2020

Oasmia Pharmaceutical AB (publ). Year-end report for the financial year May 1, 2019 – April 30, 2020

Regulatory
May 14, 2020

Oasmia Pharmaceutical supplements bulletin from Extraordinary General Meeting

Regulatory
May 14, 2020

Oasmia Pharmaceutical Announces Results of Extraordinary General Meeting and Board Changes

Regulatory
May 13, 2020

Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company

Regulatory
April 17, 2020

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

Regulatory
April 17, 2020

Oasmia Nomination Committee suggest changes in the Board of Directors

Regulatory
March 27, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1, 2019 – January 31, 2020

Regulatory
March 25, 2020

Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and double digit royalties.

Regulatory
February 14, 2020

Oasmia appoints new CEO

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com